A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Active:	No
Cancer Type:	Breast Cancer	NCT ID:	NCT04247126
Trial Phases:	Phase I	Protocol IDs:	SY-5609-101 (primary) NCI-2020-03935
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Syros Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT04247126

Summary

The study consists of 2 parts. Part 1 is dose escalation and will first administer
SY-5609 alone to participants with select advanced solid tumors and then in combination
with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is
a dose expansion and will first administer SY-5609 in combination with gemcitabine and
then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with
pancreatic ductal adenocarcinoma (PDAC) .

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.